US CDC expects COVID and RSV levels to increase in coming weeks
Adds background on vaccines in paragraphs 4,5 and vaccination details in paragraph 6
Nov 20 (Reuters) -The U.S. Centers for Disease Control and Prevention said on Wednesday it expects to see an increase in levels of COVID-19 and respiratory syncytial virus (RSV) in the country in the coming weeks, as they usually do during the holiday season.
Large gatherings, travel and more time indoors, which typically happen during the holiday season, tend to cause more viruses to spread easily, the health agency said.
CDC expects hospitalizations for flu and COVID-19 to start increasing in the coming weeks. It also sees increased RSV activity, particularly in young children, in the southern and eastern U.S.
The U.S. Food and Drug Administration had approved updated COVID-19 vaccines made by Pfizer PFE.N and its German partner BioNTech 22UAy.DE, as well as Moderna MRNA.O in August. The health regulator also granted emergency use authorization for Novavax's NVAX.O traditional protein-based shot.
Currently, there are three FDA-approved RSV vaccines made by GSK GSK.L, Moderna and Pfizer.
As of Oct. 5, 11.2% of adults aged 18 years or above received an updated COVID-19 vaccine and 36.9% of adults 75 years or older received an RSV shot, according to CDC data.
Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
